AI is reshaping how biopharma discovers, develops, and advances therapeutic agents across the full lifecycle, from early design to translational strategy and clinical asset development. But with dozens of platforms and models emerging, R&D leaders face a strategic crossroads: should they build internal AI capabilities, buy turnkey software, or partner with integrated platforms that connect computational design, experimental validation, and clinical decision-making? This session brings together Biotech R&D executives and AI platform leaders to explore how software-first, closed-loop AI workflows are transforming not only discovery speed, but also translational success and clinical outcomes. Speakers will share real-world perspectives on integrating AI into portfolio strategy, advancing assets toward the clinic, repositioning clinically validated assets, and redefining the operating model for biologics development.